Trial Profile
Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 25 Nov 2021
Price :
$35
*
At a glance
- Drugs OTS 167 (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Proof of concept
- Sponsors OncoTherapy Science
- 15 Nov 2021 Status changed from recruiting to discontinued.
- 06 Apr 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 06 Apr 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.